Nanoform Partners with Revio Therapeutics
Nanoform Finland Plc announced a partnership with Revio Therapeutics to develop GLIORA, a nano-formulated combination of olaparib and temozolomide.
The treatment is designed as a locally-administered, long-acting, thermo-responsive hydrogel for high-grade glioma, a fast-growing and aggressive type of brain tumor.
- Partners: Nanoform Finland Plc and Revio Therapeutics
- Treatment: GLIORA, a combination of olaparib (Lynparza®) and temozolomide (Temodar®)
- Target: High-grade glioma, a fast-growing and aggressive type of brain tumor
No direct quote available in the given text.
Author's summary: Nanoform partners with Revio Therapeutics to develop a treatment for glioma.
More News
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- Queer Issues are Human Issues - The McGill Daily
- Novartis Agrees to Acquire Avidity Biosciences
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Confronting deepfakes - Opinion News | The Financial Express
- Racial Disparities Persist in Victim Compensation for Homicide Survivors
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- US contractor agrees to deep-water pact with Shell